Pfizer Ends Drug Trial Early with Positive Results
May 27, 2010
According to the Associated Press, Pfizer Inc. will stop recruiting for a clinical trial of the drug Inspra in heart patients after the study reached its primary efficacy endpoint early. The world''s largest drugmaker said patients treated with Inspra and the current standard of care had a significant reduction in the risk of cardiovascular death or heart failure hospitalization compared to people treated with a placebo and the standard of care. The trial focused on patients with mild chronic systolic heart failure and left ventricular systolic dysfunction, the New York company said. The trial had an estimated end date around October 2011, and the decision to stop recruiting was based on the recommendation of an independent executive steering committee.